The Use of Artificial Intelligence for the Prediction of Recurrence After Resection of Colorectal Liver Metastases

Recruiting Observational Study
Colorectal Liver Metastasis (CRLM) Liver Resection Hepatectomy Liver Ablation
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
1,000 (estimated)
Sponsor
Francesco De Cobelli · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Colorectal cancer is the third most common cancer worldwide and the fourth most common cause of cancer-related death. Survival is primarily determined by stage of disease and the presence of metastases. The combination of chemotherapy and liver resection remains the treatment option with the highest survival benefit for patients with liver metastases from colorectal cancer, with surgery still bein…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Pathologically confirmed diagnosis (at final pathology) of liver metastases from colon or rectal adenocarcinoma * \> 6 months of follow-up * no other concomitant neoplastic disease Exclusion Criteria: * All subjects receiving hepatic resection but not fulfilling the inclusio…
Contacts

Francesco De Cobelli, MD

390226432529

trialcliniciradiologia@hsr.it

CONTACT

Stephanie Steidler, PhD

390226432529

trialcliniciradiologia@hsr.it

CONTACT